| Oct 17 |
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024
|
| Oct 9 |
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ...
|
| Sep 25 |
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
|
| Sep 4 |
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
|
| Aug 16 |
DURECT Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Aug 14 |
DURECT files for $250M mixed securities shelf
|
| Aug 14 |
DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
|
| Aug 13 |
DURECT GAAP EPS of -$0.12 beats by $0.05, revenue of $2.2M misses by $0.29M
|
| Aug 13 |
Durect: Q2 Earnings Snapshot
|
